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Abstract
Recent developments in the field of genetics have accelerated our understanding of the aetiology of complex diseases. Type 2
diabetes mellitus and cancer are no exception, with large-scale genome-wide association studies (GWAS) facilitating exploration
of the underlying pathology. Here, we discuss how genetics studies can be used to investigate the relationship between these
complex diseases. Observational epidemiological studies consistently report that people with type 2 diabetes have a higher risk of
several types of cancer. Indeed, type 2 diabetes and cancer share many common risk factors, such as obesity, ageing, poor diet
and low levels of physical activity. However, questions remain regarding the biological mechanisms that link these two diseases.
Large-scale GWAS of type 2 diabetes and cancer allow us to consider the evidence for shared genetic architecture. Several shared
susceptibility genes have been identified, yet tissue specificity and direction of effect must be taken into account when consid-
ering common genetic aetiology. We also consider how GWAS, and associated techniques such as Mendelian randomisation,
allow us to dissect the link between the two diseases and address questions such as ‘Does type 2 diabetes cause cancer or is the
increased risk observed driven by higher adiposity or another associated metabolic feature?’
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Abbreviations
GRS Genetic risk score
GWAS Genome-wide association studies
HNF1B Hepatocyte nuclear factor 1 homeobox B
IGF-1 Insulin-like growth factor 1
JAZF1 JAZF zinc finger 1
KLF14 Kruppel-like factor 14
MR Mendelian randomisation
PPARγ Peroxisome proliferator-activated receptor γ
RCT Randomised controlled trial
TCF7L2 Transcription factor 7 like 2
Introduction
Of the 4.7 million people in the UK (>450 million worldwide)
with diabetes, ~90% have type 2 diabetes mellitus [1].
Observational epidemiological studies have consistently
reported that people with type 2 diabetes have a higher risk
of certain types of cancer (not prostate cancer, where an
inverse relationship has been reported) [2]. Although type 2
diabetes is typically diagnosed by elevated levels of circulat-
ing glucose, it presents as a collection of metabolic features,
some of which may influence cancer development whereas
others may not. To date, the biological mechanisms principal-
ly hypothesised to support associations between type 2 diabe-
tes and cancer include hyperglycaemia, hyperinsulinaemia,
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sex hormone dysregulation and chronic low-grade inflamma-
tion [2]. However, questions remain as to the exact features of
type 2 diabetes that drive the association and whether they are
causal.
Here, we focus on the contribution to this field made by
genetics studies and on the insights these studies have provid-
ed in elucidating the link between type 2 diabetes and certain
types of cancer. First, we discuss whether shared genetic
aetiology may explain the increased risk of cancer in people
with type 2 diabetes (i.e. horizontal pleiotropy: genetic vari-
ants associated with type 2 diabetes are also independently
[via different mechanisms] associated with cancer risk).
Second, we consider the evidence for vertical pleiotropy (i.e.
a causal path from type 2 diabetes [or a particular metabolic
feature of type 2 diabetes] to cancer development) by apprais-
ing the evidence fromMendelian randomisation (MR) studies
(Fig. 1 and Text box: Mendelian randomisation).
Horizontal pleiotropy: do type 2 diabetes
and cancer share common genetic aetiology?
Since the advent of genome-wide association studies (GWAS)
in 2005, major progress has beenmade in our understanding of
complex diseases including type 2 diabetes and cancer [3, 4].
Type 2 diabetes itself and the cancer types observationally
associated with it are relatively common, yet high-impact vari-
ants that cause monogenic forms of diabetes or heritable cancer
syndromes are exceedingly rare and tend to result in early-
onset disease. GWAS have revealed that the inherited contri-
bution to more prevalent, later-onset disease is comprised of
many common variants, with each individual variant having a
relatively small impact [3]. Here, we discuss whether common
risk alleles predispose to both type 2 diabetes and particular
cancers and whether this can explain the observed association
between type 2 diabetes and particular cancer types. We
discuss examples that provide the most convincing evidence
for shared genetic aetiology between the two diseases, discuss
shared susceptibility genes and highlight scenarios that may
result in misinterpretation of common aetiology.
Evidence for type 2 diabetes risk alleles increasing risk of
cancer Several types of cancer, including liver, pancreatic,
endometrial, breast, colorectal, bladder and kidney cancer
and non-Hodgkin’s lymphoma, have been positively and
observationally associated with type 2 diabetes [5].
However, evidence for shared genetic aetiology between type
2 diabetes and these cancers is scarce. Several type 2 diabetes
susceptibility genes are associated with cancer development,
yet this does not necessarily imply shared genetic aetiology.
This would be demonstrated by the identification of the same
genetic variant and risk allele (or those in linkage disequilib-
rium) that independently predisposes to both type 2 diabetes
and cancer (Fig. 1a). Genetic variation at TCF7L2 (transcrip-
tion factor 7 like 2) is perhaps the best and most extensively
studied example of this.
The transcription factor encoded by TCF7L2 operates at
the last stage of the canonical Wnt signalling transduction
cascade [6]. Genetics studies have reported a positive associ-
ation between type 2 diabetes predisposing alleles within
TCF7L2 and cancer including colorectal [7–9], breast
[10–12] hepatocellular [13] and aggressive prostate cancer
[14]. A recent comprehensive meta-analysis found type 2
diabetes risk alleles at eight variants in TCF7L2 were associ-
ated with increased risk of breast, colorectal and lung cancer
and glioma [15].
The association between type 2 diabetes risk alleles in
TCF7L2 and higher risk of colorectal cancer has been repli-
cated in several studies [7, 16, 17]. The Wnt pathway is
a major driver of colorectal carcinogenesis and the
What is Mendelian randomisation?
Mendelian randomisation (MR) is an analytical method that uses genetic variants as proxies for potentially modifiable 
exposures (e.g. environmental factors or biological traits) to permit causal inference when interpreting relationships 
between these factors and disease outcomes [105].
MR study design
The design of an MR study is analogous to that of an RCT. In an RCT, to minimise confounders and selection biases, 
participants are randomly assigned to two groups. Each group will receive a different treatment/management. Because 
assignment to each group happens at the start of the study, reverse causation can generally be ruled out. In using an 
MR strategy to investigate the causal association between type 2 diabetes and cancer, individuals are randomised 
according to inferred type 2 diabetes liability using genetic variants (taken from GWAS) known to predispose individuals 
to type 2 diabetes and asks whether the groups differ with regard to cancer risk. Because the assignment of genetic 
variants is random from parents to offspring and is largely independent of environment, lifestyle and the outcome of 
interest (cancer), it is less susceptible to confounding or reverse causation.
Mendelian randomisation
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TCF7L2 gene is frequently mutated in colorectal cancer
[18]. The association with colorectal cancer has been
shown to be independent of type 2 diabetes or obesity
[7, 16, 17], suggesting the risk alleles are likely to have
greatest impact specifically in colon tissue and not in
the pancreatic islet (which is likely to mediate the
impact of the variants on type 2 diabetes).
Studies investigating a number of different type 2 diabetes
predisposing variants in relation to cancer risk have reported
only a small number of weak associations and findings are
often inconsistent. In one study, among 37 type 2 diabetes risk
alleles, two (in FTO and MTNR1B) showed nominally posi-
tive associations with pancreatic cancer risk and one showed
an inverse association (in BCL11A) [19]. In another, among
33 type 2 diabetes risk alleles, three (in FTO, TCF7L2 and
PRC1) were found to be associated with breast cancer [20].
Inconsistently, two additional studies have shown null associ-
ations with breast cancer across all type 2 diabetes variants
tested [21, 22].
Directionality of type 2 diabetes risk alleles on cancer risk
Observational epidemiology shows several cancers to be posi-
tively associated with type 2 diabetes; however, prostate cancer
has been consistently found to be inversely associated. In
agreement, several type 2 diabetes risk alleles have been found
to associate with reduced risk of prostate cancer. Type 2 diabe-
tes risk alleles in PPARG (encoding peroxisome proliferator-
activated receptor γ [PPARγ]) [23, 24] andHNF1B (encoding
hepatocyte nuclear factor 1 homeobox B) [25] lower the risk of
prostate cancer. One study found that 10 out of 36 type 2
diabetes risk alleles were nominally inversely associated with
prostate cancer, with only the HNF1B risk allele remaining
significant following multiple testing correction [26].
Another study found that four of 13 type 2 diabetes predispos-
ing alleles were nominally inversely associated [27]. Using a
genetic risk score (GRS) consisting of 18 type 2 diabetes risk
variants, it has been shown that people with higher genetic
susceptibility to type 2 diabetes have a reduced risk of prostate
cancer [28]. However, some studies have found no association
between type 2 diabetes risk variants (either individually or in
risk scores) and prostate cancer [29, 30].
Genetic variants in JAZF1 (encoding JAZF zinc finger 1)
also have an inverse effect on the relationship between type 2
diabetes and prostate cancer. A recent GWAS found two
genetic variants in JAZF1, one with a major allele predispos-
ing to type 2 diabetes [31] and the other with a major allele
protecting against prostate cancer [32]. As the genetic variants
are not correlated (not in linkage disequilibrium), they may
operate through different pathways to alter type 2 diabetes and
prostate cancer risk, respectively. This example highlights
how genetic variation in the same gene can affect the risk of
two diseases without necessarily meaning that the diseases
share genetic aetiology.
The direction of effect of type 2 diabetes risk alleles on
cancer is often not clear-cut, with some type 2 diabetes predis-
posing alleles in the same gene increasing the risk of one cancer
but protecting against another. For example, type 2 diabetes risk
alleles in PPARG are associated with elevated risk of pancreatic
cancer [33] and reduced risk of colorectal cancer [34]. This
pattern of association suggests the role of PPARG likely
depends on the context and should be interpreted accordingly.
This finding is also consistent with the described multifaceted
role of PPARγ in cancer, wherein it exhibits both tumour-
suppressive and tumour-promoting properties [35]. Similar
evidence comes from HNF1B, for which type 2 diabetes risk
alleles are associated with ovarian cancer but the direction of
effect varies by subtype (serous vs clear cell) [36, 37].
Shared susceptibility genes: directionality, tissue specificity
and context Several common susceptibility genes have been
implicated in type 2 diabetes and particular cancers but there is
currently little evidence for shared genetic aetiology for many
of these. For example, common variants in KLF14 (encoding
Kruppel-like factor 14, an imprinted transcription factor),
associated with lower expression in adult adipose tissue, cause
a defect of adipogenesis that is likely to reflect impaired
glucose uptake and consequently higher risk of type 2 diabetes
[38]. KLF14 expression is reduced in many types of human
cancer, including breast, lymphatic, cervical, oral cavity, floor
of mouth, pancreas and colorectal cancers [39]. Despite
reduced expression having been associated with both type 2
diabetes and certain types of cancer, further studies are needed
to investigate whether type 2 diabetes predisposing alleles
resulting in reduced expression of KLF14 are also associated
with risk of the implicated cancers.
GWAS of type 2 diabetes have consistently identified vari-
ants (or colocalising variants) in genes implicated in prolifer-
ation and cell cycle regulation [40, 41]. These hallmarks are
traditionally associated with cancer; however, direction of
effect and tissue specificity are key here. As an illustration,
type 2 diabetes risk alleles identified at the CDKN2A/B locus
[41] have been implicated in reduced beta cell function [42,
43]. Transgenic mice overexpressing CDKN2A/B display
decreased islet proliferation [44], suggesting that the type 2
diabetes risk alleles influence pathology by increasing
CDKN2A/B expression. Conversely, rare CDKN2A loss-of-
function mutations cause familial melanoma and individuals
carrying these mutations have improved beta cell function
[45]. The direction of effect here is clearly opposing and even
though the gene is implicated in both diseases, the context is
vastly different and they would not be expected to share risk
alleles at these loci. An important consideration when evalu-
ating evidence for shared genetic aetiology is that many type 2
diabetes predisposing variants are in pancreatic islet enhancers
and are therefore unlikely to be implicated in cancer develop-
ment in other tissues.
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Furthermore, type 2 diabetes predisposing variants in genes
involved in the insulin signalling pathway are expected to have
an opposing direction of effect on cancer. Variants inAKT2 and
PTEN have been associated with type 2 diabetes risk; their
presence reduces activity of the insulin signalling pathway,
leading to reduced glucose uptake and insulin resistance in
insulin-responsive tissues. Conversely, tumour cells would
typically benefit from enhanced activity of this pathway
(through pro-proliferative and anti-apoptotic signals). Indeed,
PTEN (a negative regulator of the pathway) and AKT2 are
well-characterised tumour suppressor and oncogenes, respec-
tively. Indeed, loss-of-function mutations in PTEN cause a rare
cancer-predisposition syndrome and protect against type 2
diabetes (through enhanced insulin sensitivity) [46].
Summary Several type 2 diabetes susceptibility genes are known
to play a role in cancer development (e.g. TCF7L2, CDKN2A/B,
AKT2,PPARG,PTEN andHNF1B) but the evidence is relatively
scarce for shared genetic aetiology between type 2 diabetes
predisposing alleles and the observationally associated cancers.
However, there are particular contexts wherein the evidence
appears consistent and persuasive: the positive association
between type 2 diabetes risk alleles in TCF7L2 and higher risk
of breast and colorectal cancer; and the association between type
2 diabetes predisposing alleles and lower risk of prostate cancer.
What quickly becomes apparent when appraising the role of
type 2 diabetes susceptibility genes in the development of a
particular cancer is that the situation is very rarely clear-cut.
Several genes are implicated in both diseases yet in most cases
type 2 diabetes predisposing alleles have not been found to be
associated with a cancer and often the biological impact of these
alleles would be expected to protect against, rather than predis-
pose to, cancer. When evaluating evidence from genetics studies,
it is important to consider that in many of the studies the identity
of the gene (or genes) through which the type 2 diabetes predis-
posing variants act has been assumed. The gene is easy to identify
if the variant is in a coding region but most loci are in non-protein
coding regions of the genome, making it difficult to determine
how the variant impacts disease development. While some
elegant work is being carried out in this area [47], further work
is needed in the functional annotation of type 2 diabetes predis-
posing variants. Extrapolating this to determine how the gene
may behave in the context of cancer is further complicated by
the fact that cancer is very much not one disease. Cancers devel-
oping at different sites (and indeed different cancer subtypes
developing at the same site) will be exposed to different environ-
ments, acquire different mutations and will invariably develop
differently. Therefore, directionality, tissue specificity and context
are key considerations when assessing evidence for shared genet-
ic aetiology between type 2 diabetes and a particular cancer.
Vertical pleiotropy: using genetic variants
to investigate a causal pathway to cancer
through type 2 diabetes
Despite the lack of convincing evidence that shared genetic
aetiology explains the observed positive association between
type 2 diabetes and risk of a particular cancer, an observational
correlation between diabetes and cancer quite clearly exists.
Genetic 
variant
Risk of type 2 diabetes
Risk of cancer
















Fig. 1 The relationship between type 2 diabetes and cancer. (a) The
increased risk of cancer in people with type 2 diabetes could be due to
shared genetic aetiology between the two diseases. In this scenario, genet-
ic variants that predispose individuals to type 2 diabetes would also
predispose individuals to cancer. The relationship between type 2 diabe-
tes and cancer is therefore horizontal, as the effect of the genetic variant
on each disease is independent and is exerted through different mecha-
nisms. (b) The increased risk of cancer in people with type 2 diabetes may
be due to a tumorigenic effect driven by either type 2 diabetes
itself or an associated trait (such as adiposity). This is an example
of vertical pleiotropy, as there is a linear pathway from type 2
diabetes (or associated trait) to cancer. MR uses genetic variants
as a proxy for the exposure of interest to assess whether there is
a vertical causal pathway from the exposure to the outcome. This
figure is available as part of a downloadable slideset
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To explore this further, we will appraise the evidence gained
from genetics studies employing an MR strategy for a vertical
(causal) pathway from type 2 diabetes (or a particular meta-
bolic feature of type 2 diabetes) to cancer (Fig. 1b).
Determining whether there is a causal relationship between
type 2 diabetes and cancer has been challenging. Observational
epidemiological studies are limited due to certain biases includ-
ing confounding, measurement error and reverse causation.
Confounders are factors that may independently influence both
the risk of type 2 diabetes and risk of cancer (e.g. alcohol
consumption, adiposity and lower socioeconomic status).
Reverse causation is also an important consideration, since
the development of certain cancers can precede and cause the
development of type 2 diabetes (e.g. pancreatic and liver cancer
[problems with traditional epidemiological studies in this
context are discussed further here [5, 48]]).
The gold standard study design for inferring causality is a
randomised controlled trial (RCT), but it would be ethically
unsound and methodologically unfeasible to apply this frame-
work to the question of whether type 2 diabetes causes cancer.
A safe, inexpensive alternative is to use a genetic approach:MR
[49], essentially a genetic analogue of the RCT [3] (Fig. 2 and
Text box: Mendelian randomisation). This powerful use of
genetics allows researchers to consider how key environmental
and lifestyle factors (e.g. type 2 diabetes) influence complex
diseases (e.g. cancer). Certain assumptions must be satisfied
in order to perform MR (Fig. 2) and there are particular limita-
tions and considerations when performing MR with cancer as
the outcome (comprehensively reviewed elsewhere [50]).
Several studies have used MR to investigate whether there
is a causal association between type 2 diabetes and cancer.
These studies typically use a GRS composed of type 2 diabe-
tes predisposing genetic variants weighted according to their
effect on type 2 diabetes risk. These studies are in agreement
in that they find no evidence for an association between the
two diseases [51–55], consistent with the lack of evidence
from studies assessing the association of single type 2 diabetes
predisposing genetic variants and cancer.
AlthoughMR studies do not support a role for type 2 diabetes
in cancer development, a number of factors should be consid-
ered when interpreting these findings. First, power for an MR
study is influenced by the statistical power of the GWAS used.
Sample sizes are lower for cancer GWAS than for cardiometa-
bolic disease GWAS, for instance, due to the rarer nature of the
disease. Lack of power may limit the ability to detect smaller
causal effects using MR. Second, some type 2 diabetes genetic
variants have a paradoxical association with the classically
defined metabolic features of type 2 diabetes (e.g. a variant in
KCNQ1 is associated with both hyperglycaemia and
hypoinsulinaemia [52]). These paradoxical associations could
potentially cancel each other out. Finally, and most importantly,
type 2 diabetes is a markedly complex and heterogeneous
disease. It is characterised by a collection of metabolic events
and each affected individual presents with a different contribu-
tion of metabolic features. Therefore, the observational associa-
tion between type 2 diabetes and cancer may be driven by a
particular metabolic trait of type 2 diabetes or by an associated
condition, such as obesity. Below, we discuss the important
metabolic traits thought to influence cancer risk in conjunction
with evidence from MR studies.
Hyperglycaemia The diagnostic hallmark of type 2 diabetes is
hyperglycaemia. Several observational epidemiological stud-
ies have reported a positive correlation between fasting
glucose levels and risk of and survival from particular cancers
















Fig. 2 The assumptions of the MR approach. To perform MR, three
assumptions (green arrows) need to be satisfied. First, the genetic variants
used to proxy the risk factor need to be robustly associated with it.
Second, these variants need to be independent of any confounding
factors. Third, the variants should only be associated with the outcome
through their effect on the risk factor. This figure is available as part of a
downloadable slideset
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cells preferentially use glucose as their main source of energy
and become ‘addicted’ to the pathways processing the sugar in
the cell. However, there is little evidence to suggest that
tumour cells benefit energetically from hyperglycaemia over
and above normoglycaemic conditions [61]. Consistent with
this, a meta-analysis of RCTs of intensified glycaemic control
did not find evidence of any cancer risk reduction in people
with type 2 diabetes [62].
Similarly, MR studies have been unable to support a role for
hyperglycaemia in cancer development. Genetic variants infer-
ring lifelong differences in fasting glucose were not associated
with lung [63], endometrial [53] or pancreatic cancer [51] or
renal cell carcinoma [54]. However, genetic variants inferring
differences in 2 h (post-challenge) glucosewere positively asso-
ciated with breast cancer, despite there being no association
with fasting glucose in the same study [64]. While this suggests
that postprandial glucose levels may be pertinent for cancer
development, further investigation is required.
Hyperinsulinaemia Several observational epidemiological
studies have demonstrated that high levels of endogenous insu-
lin are associated with higher risk of cancer incidence and
mortality, including risk of colorectal [65], endometrial [66,
67], prostate [68] and breast cancer [69, 70] and breast cancer
mortality [71]. Unlike the findings with hyperglycaemia, MR
studies support a causal association between higher levels of
fasting insulin and risk of endometrial [53], breast [64], lung
[63] and pancreatic cancer [51] and renal cell carcinoma [54].
With the exception of higher body fatness, this is by far the
most consistent association between a type 2 diabetes-related
trait and particular cancers in studies using an MR framework,
although replication studies confirming the association found
for particular cancers are lacking.
There are several explanations for the causal role of insulin,
directly or indirectly, in cancer incidence and risk of mortality.
Insulin and insulin-like growth factor 1 (IGF-1) may locally
contribute to tumour cell proliferation [72]. Observational epide-
miological studies have reported a positive link between circu-
lating IGF-1 levels and increased risk of particular cancers,
although associations vary between sites [73]. Evidence from
MR studies implicate circulating IGFs in breast cancer [74] and
prostate cancer risk and progression [75, 76]. Another purported
mechanism is that hyperinsulinaemia inhibits the production of
sex hormone binding globulin (SHBG) in the liver, resulting in
an elevation of free hormones (including oestrogen and testos-
terone), which are pro-proliferative and anti-apoptotic [77].
Consistent with this, MR studies have reported an association
between sex hormones and puberty timing and breast and endo-
metrial cancer in women [78–80] and between puberty timing
and prostate cancer in men [78].
AdiposityAmong the risk factors shared by type 2 diabe-
tes and cancer, the most dominant and the most likely
to confound observational epidemiology is adiposity.
Evidence from observational studies suggests there is a
positive relationship between excess body fatness and
the risk of 13 cancer types [81]. In support of this,
observational studies of weight loss [82] and follow-up
studies of patients undergoing bariatric surgery [83]
show that weight reduction lowers cancer risk.
Several MR studies support a causal association between
higher body fatness and risk of six obesity-related cancers
[84], renal cell carcinoma [54], endometrial [85], ovarian
[55, 86, 87], oesophageal [88], pancreatic [51, 89, 90] and
colorectal cancer [87, 91] and reduced survival in oestrogen
receptor-positive (ER+) breast cancer [92]. Higher body
fatness has also been found to be causally associated with lung
cancer [63, 87], a cancer not observationally associated with
higher adiposity or type 2 diabetes. The same study also found
a positive association between fasting insulin levels and lung
cancer, which may mean we need to re-evaluate the cancers
we think of as being associated with metabolic dysregulation.
The weight of evidence therefore suggests there is a causal
path between higher adiposity and risk of particular cancers.
Effort will now need to be directed into investigating which
aspects of excess adiposity are important. Adiposity is a
complex phenotype and is associated with considerable meta-
bolic and endocrine abnormalities, therefore it may be meta-
bolic dysfunction that increases the risk of cancer, rather than
a higher level of body fat per se. In support of this, despite
several metabolic features of type 2 diabetes being found to be
positively associated with breast cancer, higher adiposity has
been found to have a protective effect in MR studies of both
pre- and postmenopausal women [64, 87, 93, 94]. This
suggests that the association between metabolic features such
as increased fasting insulin levels and breast cancer risk may
be independent of higher adiposity. However, observational
studies have consistently reported a positive association
between high BMI and postmenopausal breast cancer, further
emphasising that the relationship between BMI and breast
cancer is not straightforward. How weight is gained and when
across the life course may be important; there is strong
evidence from a recent MR study of a protective effect for
larger body size in early life with breast cancer risk, with little
evidence for an association with adult body size [95].
MR provides a means to uncouple the impact of higher
adiposity from its often associated metabolic dysfunction by
using genetic variants associated with ‘favourable adiposity’.
The adiposity-increasing alleles at these loci have a paradox-
ical effect on adiposity and risk of cardiometabolic disease
[96–98] and are associated with a favourable metabolic
profile. Studies using MRI scans of abdominal fat suggest that
the underlying mechanism involves an ability to store excess
fat in a safe place (subcutaneous adipose tissue), which
protects against fat accumulation in ectopic organs like the
liver [98]. Employing MR studies to consider the role of
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favourable vs unfavourable adiposity in cancer risk will
indeed be intriguing.
Conclusions and future work
Here, we have considered the evidence from genetics studies that
supports the observed association between type 2 diabetes and
particular cancers. It is important to consider these studies in the
context of the broader scientific literature. Thorough investigation
of the link between type 2 diabetes and particular cancers requires
the accumulation of several strands of evidence from studies
across diverse methodologies including triangulating evidence
across observational and genetic epidemiological studies and
animal and laboratory-based studies. Indeed, observational and
genetic epidemiological studies have different biases, strengths
and weaknesses. Hence, if results are in agreement across differ-
ent methodologies, they are more likely to be robust [99].
Based on appraisal of the available evidence from genetics
studies it seems unlikely that the observational association
between type 2 diabetes and cancer risk is driven by shared
genetic aetiology. It seems more likely to be driven by a partic-
ular metabolic feature of type 2 diabetes itself, such as increased
fasting insulin levels, or by an associated trait, such as higher
adiposity, as demonstrated by MR studies (summarised in Fig.
3). However, further work is needed to fully define this
complex relationship and to elucidate the underlying biological
mechanisms. Recently, interest has grown in deconstructing or
partitioning the type 2 diabetes GRS, grouping the genetic vari-
ants in relation to their biological role [100–102]. MR can then
be employed to assess the causal association between the
groups and various cancer types. This could help shed further
light on what aspects of this heterogeneous disease are most
influential in cancer development and help unpick the underly-
ing mechanisms. In future studies it might also be possible to
use MR to explore the potential of particular therapeutic strat-
egies (see Text box: Translational relevance for genetics studies
in type 2 diabetes and cancer). It is also likely that epigenetic
alterations (driven by type 2 diabetes or associated metabolic
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No evidence for a causal association between 
T2DM and overall [52], pancreatic [51,89], 
endometrial [53], RCC [54] or ovarian [55] cancer
No evidence for a causal association between 
glucose measures and lung [63], pancreatic [51, 
89] and endometrial cancer [53] and RCC [54]; 
some evidence of an association between 2 h 
glucose and breast cancer [64]
Evidence for an association between higher levels 
of fasting insulin and risk of endometrial [53], 
breast [64], lung [63] and pancreatic cancer [51] 
and RCC [54] 
Some evidence implicating circulating IGFs in 
breast cancer [74] and prostate cancer risk [75, 76] 
Some evidence implicating sex hormone levels and 
puberty timing with breast and endometrial cancer 
in women [78–80] and puberty timing in prostate 
cancer in men [78]
Evidence for a causal association between 
adiposity measures and RCC [54] and endometrial 
[85], ovarian [55, 86, 87], oesophageal [88], 
pancreatic [51, 89, 90] and colorectal [87, 91] 
cancer
Cancer type investigated
Fig. 3 Summary of evidence from MR studies supporting an association
between type 2 diabetes (or associated metabolic traits) and cancer. Type
2 diabetes is a complex heterogeneous disease, characterised by a collec-
tion of metabolic events and each affected individual presents with a
different contribution of metabolic features. MR allows us to consider
the causal relationship between type 2 diabetes (when considered as a
whole and also each metabolic trait in isolation) and cancer. This
approach allows us to investigate whether a particular metabolic trait is
responsible for the increased risk of cancer in people with type 2 diabetes.
In the figure, the strength of evidence supporting a causal association is
defined as follows: none, no evidence for a causal association between
trait and cancer; weak, only one study reports a causal association
between trait and cancer; moderate, more than one study reports a consis-
tent causal association; strong, several studies report a consistent causal
association but replication is limited; very strong, several studies report a
consistent causal association and several studies have replicated analyses
in the same and some in different cohort data sets. RCC, renal cell carci-
noma; T2DM, type 2 diabetes mellitus. This figure is available as part of a
downloadable slideset
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genetics studies have the potential to help us explore this further
[103].
There are several areas that need further exploration. In partic-
ular, genetics studies of type 2 diabetes and cancer progression
are largely lacking. A recent analysis where this has been
attempted used 143 type 2 diabetes predisposing variants and
investigated their association with risk of mortality in ~800
people. Twelve SNPs were associated with risk of breast cancer,
threewith all-causemortality and threewith breast cancer specific
mortality, yet none of the associationswere significant aftermulti-
ple testing corrections [104]. Until data from larger cohorts are
available, power is likely to be an issue in such studies. Although
a handful ofMR studies have been undertaken on type 2 diabetes
(or related traits) and cancer progression, methodological chal-
lenges remain, such as selection bias (discussed further here [50]).
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Genetic risk profiling
The identification of common risk alleles for complex diseases by GWAS has sparked interest in the potential for genetic 
risk profiling (e.g. polygenic risk scores can be used to identify people with a particularly high risk of type 2 diabetes
[3]). Could this approach be used to identify people with type 2 diabetes who might be at increased risk of developing 
cancer? This would require identification of a large number of genetic variants in people with type 2 diabetes that 
increase cancer risk. As we have discussed, evidence for shared genetic aetiology is sparse, therefore this is currently 
a long way off, if ever a possibility.
Cancer prevention strategies in people with type 2 diabetes
Interventions to prevent cancer in people with type 2 diabetes will require knowledge of the particular metabolic traits 
that most influence the connection between the two diseases. Therefore, perhaps most likely to have future clinical 
benefit would be the use of MR to identify these features to enable intervention through their modification. These studies 
will also shed light on the underlying mechanistic link connecting type 2 diabetes and cancer and may highlight potential 
intervention targets for prevention and therapy.
Prioritisation or repurposing of type 2 diabetes drugs to lower cancer risk
Genetics studies also offer the opportunity to investigate prioritisation or repurposing of type 2 diabetes drugs to lower 
cancer risk. Several drug targets for type 2 diabetes possess genetic variants that are causally associated with the 
disease (e.g. thiazolidinediones targeting PPARG could potentially be used to simultaneously treat type 2 diabetes and 
reduce risk of particular cancers). There has been interest in the glucose-lowering drug metformin as a cancer 
preventative agent. Several promising observational studies suggest that metformin has anti-cancer properties. How-
ever, unmeasured confounding and immortal time bias in studies on diabetes medications in relation to cancer risk are 
a significant problem (reviewed here in detail [5]). Genetics studies have the potential to contribute to this field, although 
a real challenge, particularly with regard to metformin, will be to identify an appropriate genetic proxy. Two recent MR 
studies using genetic variants to proxy for metformin treatment found no association with risk of breast, prostate or 
colorectal cancer [106, 107]. However, although the proxies used may mediate some of the effects of metformin, they 
are extremely unlikely to mediate them all, therefore further work is clearly needed [108].
Translational relevance for genetics studies in                
type 2 diabetes and cancer
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